Loading company…
Onegene Biotechnology develops protein-based therapeutics for chronic diseases and cancer.
Founded in 2016 and based in South Korea, Onegene Biotechnology develops multi-targeting tri- or tetra-specific protein drugs for NASH, fibrotic diseases, and cancers. Its UniStac platform uses enzyme-mediated protein conjugation technology. In May 2022, the company raised KRW 40.7 billion in Series B funding from BNH Investments, Devsisters Ventures, ESV Investments, Korea Investment & Securities, Medici Investments, Premier Partners, Quantum Ventures Korea, Shinhan Venture Investment, Solid's Investments, Stick Ventures, Time Folio Asset Management, and UTC Investments. CEO Dr. Sungjin Park led the company as of 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in